Sepsis: Lessons learned in the last century and future directions

Archives of Surgery

Volumn 134, Issue 9, 1999, Pages 922-929

  Chaudry, Irshad H ^a,b  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CHLOROQUINE; CORTICOSTEROID; DILTIAZEM; ENDOTOXIN; FLUTAMIDE; IBUPROFEN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHYLPREDNISOLONE; METOCLOPRAMIDE; MONOCLONAL ANTIBODY; PLACEBO; PRASTERONE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TUMOR NECROSIS FACTOR ANTIBODY;

ANIMAL MODEL; ANTIBIOTIC THERAPY; CAUSE OF DEATH; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; ESCHERICHIA COLI; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHUMAN; PATHOGENESIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSEUDOMONAS; RANDOMIZED CONTROLLED TRIAL; SEPSIS; TRAUMATOLOGY; TREATMENT INDICATION; VOMITING;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; SEPSIS;

EID: 0032820318     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.134.9.922     Document Type: Conference Paper

References (108)

1. The World Health Report 1998: Life in the 21st Century: A Vision for All. Geneva, Switzerland: World Health Organization; 1998.
2. Finland M, Jones WF, Barnes MW. Occurrence of serious bacterial infections since introduction of antibacterial agents. JAMA. 1959;84:2188-2197.
3. Hemminki E, Paakkulainen A. Effect of antibiotics on mortality from infectious diseases in Sweden and Finland. Am J Public Health. 1976;66:1180-1184.
4. Barton RG, Cerra FB. Initial management of trauma: the first 5 minutes. Postgrad Med. October 1990;88:83-90.
5. Carrico CJ, Meakins JL, Marshall JC, Fry D, Maier RV. Multiple organ failure syndrome. Arch Surg. 1986;121:196-208.
6. Cerra FB. Multiple organ failure syndrome. In: Bihari DJ, Cerra FB, eds. Multiple Organ Failure. Fullerton, Calif: Society of Critical Care Medicine. 1989:1-24.
7. Field BE, Devich LE, Carlson RW. Impact of a comprehensive supportive care team on the management of hopelessly ill patients with multiple organ failure. Chest. 1989;96:353-362.
8. Baue AE, Durham R, Faist E. Systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF): are we winning the battle? Shock. 1998;10:79-89.
9. Pinner RW, Teutsch SM, Simonson L, et al. Trends in infectious diseases mortality in the United States. JAMA. 1996;275:189-193.
10. Boivin A. Bacteries et Virus. Paris, France: Presses Universtaires de France; 1941.
11. Borden CW, Hall WH. Fatal transfusion reactions from massive bacterial contamination of blood. N Engl J Med. 1951;245:760-765.
12. O'Donnell TF, Clowes GHA, Ryan NT, Blackburn GL, Weisser A. Experimental endotoxemia: does it stimulate metabolism in septic shock? Surg Forum. 1957; 26:25-26.
13. Waisbren BA. Gram-negative shock and endotoxin shock. Am J Med. 1964;36: 819-824.
14. MacLean LD, Mulligan WG, McLean APH, Duff JH. Patterns of septic shock in man: a detailed study of 56 patients. Ann Surg. 1967;166:543-562.
15. Swan KG, Jacobson ED. Hemodynamics of endotoxin shock in the conscious animal. Surg Gynecol Obstet. 1967;125:1041-1046.
16. Thal AP, Robinson RG, Pruett R, Nagamine T, Wegst AV. The critical relationship in intravascular blood volume and vascular capacitance in sepsis. Surg Gynecol Obstet 1976;143:17-22.
17. Filkins JP, Cornell RP. Depression of hepatic gluconeogenesis and the hypoglycemia of endotoxin shock. Am J Physiol. 1974;227:778-781.
18. Gump FE, Long CL, Geiger JW, Kinney JM. The significance of altered gluconeogenesis in surgical catabolism. J Trauma. 1975;15:704-713.
19. Clowes GH Jr, Zuschneid W, Turner M, et al. Observations on the pathogenesis of pneumonitis associated with severe infection in other parts of the body. Ann Surg. 1968;167:630-650.
20. Pitcairn M, Schuler J, Erve PR, Holtzman S, Schumer W. Glucocorticoid and antibiotic effect on experimental gram-negative bacteremic shock. Arch Surg. 1975;110:1012-1015.
21. Cryer PE, Herman CM, Sode J. Carbohydrate metabolism in the baboon subjected to gram-negative (E coli) septicemia, I: hyperglycemia with depressed plasma insulin concentrations. Ann Surg. 1971;174:91-100.
22. Postel J, Schloerb PR. Metabolic effects of experimental bacteremia. Ann Surg. 1977;185:475-480.
23. Walker HL, Mason AD, Raulston GL. Surface infection with Pseudomonas aeruginosa. Ann Surg. 1964;160:297-305.
24. Hermreck AS, Berg RA, Ruhlen JR, MacArthur RI. Renal response in sepsis. Arch Surg. 1973;107:169-175.
25. Hermreck AS, Thai AP. Mechanisms for the high circulatory requirements in sepsis and septic shock. Ann Surg. 1969;170:677-695.
26. Browne MK, Leslie GB. Animal models of peritonitis. Surg Gynecol Obstet 1976; 143:738-740.
27. Decker GAG, Daniel AM, Blevings S, MacLean LD. Effect of peritonitis on mitochondrial respiration. J Surg Res. 1971;11:528-532.
28. Onderdonk AB, Bartlett JG, Louis T, Sullivan-Seigler N, Gorbach SL. Microbial synergy in experimental infra-abdominal abscess. Infect Immun. 1976;13:22-26.
29. Perkash I, Satpati P, Agawal KC, Chakravarti RN, Chhuttani PN. Prolonged peritoneal lavage and fecal peritonitis. Surgery. 1970;68:842-845.
30. Sleeman HK, Diggs JW, Hayes DK, Hamit HF. Values of antibiotics, corticosteroids and peritoneal lavage in the treatment of experimental peritonitis. Surgery. 1969;66:1060-1066.
31. Hau T, Simmons RL. Animal models of peritonitis. Surg Gynecol Obstet. 1977; 144:755-756.
32. Weinstein WM, Onderdonk AB, Bartlett JG, Gorbach SL. Experimental intraabdominal abscesses in rats: development of an experimental model. Infect Immun. 1974;10:1250-1255.
33. Bartlett JG, Onderdonk AB, Louie T, Kasper DL, Gorbach SL. Lessons from an animal model of intra-abdominal sepsis: a review. Arch Surg. 1978;113:853-857.
34. Imamura M, Clowes GH Jr. Hepatic blood flow and oxygen consumption in starvation, sepsis and septic shock. Surg Gynecol Obstet. 1975;141:27-34.
35. Perbellini A, Shatney CH, MacCarter DJ, Liltehei RC. A new model for the study of septic shock. Surg Gynecol Obstet. 1978;147:68-74.
36. Wright CJ, Duff HJ, Maclean APH, MacLean LD. Regional capillary blood flow and oxygen uptake in severe sepsis. Surg Gynecol Obstet. 1971;132:637-644.
37. Wang P, Ba ZF, Chaudry IH. Hepatic extraction of indocyanine green is depressed early in sepsis despite increased hepatic blood flow and cardiac output. Arch Surg. 1991;126:219-224.
38. Chaudry IH, Wichterman KA, Baue AE. Effect of sepsis on tissue adenine nucleotide levels. Surgery. 1979;85:205-211.
39. Wichterman KA, Baue AE, Chaudry IH. Sepsis and septic shock: a review of laboratory models and a proposal. J Surg Res. 1980;29:189-201.
40. Baker CC, Chaudry IH, Gaines HO, Baue AE. Evaluation of factors affecting mortality rate after sepsis in murine cecal ligation and puncture model. Surgery. 1983;94:331-335.
41. Wang P, Ba ZF, Zhou M, Chaudry IH. Pentoxifylline restores cardiac output and tissue perfusion following trauma-hemorrhage and decreases susceptibility to sepsis. Surgery. 1993;114:352-359.
42. Witek-Janusek L, Ratmeyer JK. Sepsis in the young rat: maternal milk protects during cecal ligation and puncture sepsis but not during endotoxemia. Circ Shock. 1991;33:200-206.
43. Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med. 1987;317:659-665.
44. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednesolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317:653-658.
45. Marshall JC, Lee C, Meakins JL, Michel RP, Christou NV. Kupffer cell modulation of the systemic immune response. Arch Surg. 1987;122:191-196.
46. van der Poll T, Lowry SF. Tumor necrosis factor in sepsis, mediator of multiple organ failure or essential part of host defense? Shock. 1995;3:1-12.
47. van der Poll T, Jansen PM, Montegut WJ, et al. Effects of IL-10 on systemic inflammatory responses during sublethal primate endotoxemia. J Immunol. 1997; 158:1971-1975.
48. Fong Y, Moldawer LL, Shires GT, Lowry SF. The biological characteristics of cytokines and their implication in surgical injury. Surg Gynecol Obstet. 1990; 170:363-378.
49. 2) in traumatized individuals. In: Faist E, Meakins J, Schildberg FW, eds. Host Defense Dysfunction in Trauma, Shock and Sepsis. New York, NY: Springer-Verlag NY Inc; 1993:637-650.
50. Miller-Graziano CL, De AK, Kodys K. Altered IL-10 levels in trauma patients' macrophages and T lymphocytes. J Clin Immunol. 1995;15:93-104.
51. Lowry SF. Tumor necrosis factor and other cytokines as mediators of clinical sepsis. In: Faist E, Meakins J, Schildberg FW, eds. Host Defense Dysfunction in Trauma, Shock and Sepsis. New York, NY: Springer-Verlag NY Inc; 1993: 253-261.
52. Siegel JH. Eicosanoids, cytokines and altered metabolic control in the evolution of the posttraumatic host defense failure syndromes: adult respiratory distress syndrome and multiple organ failure syndrome. In: Faist E, Meakins J, Schildberg FW, eds. Host Defense Dysfunction in Trauma, Shock and Sepsis. New York, NY: Springer-Verlag NY Inc; 1993:199-219.
53. 2 (PGE2)-dependent suppression of interleukin alpha (IL-2) production in patients with major trauma. J Trauma. 1987;27:837-848.
54. Mannick JA. Trauma, sepsis and immune defects. In: Faist E, Meakins JL, Schildberg FW, eds. Host Defense Dysfunction in Trauma, Shock and Sepsis. New York, NY: Springer-Verlag NY Inc; 1993:15-21.
55. Yurt RW, Lowry SF. Role of the macrophage and endogenous mediators in multiple organ failure. In: Deitch EA, ed. Multiple Organ Failure. New York, NY: Thieme-Stratton Inc; 1990:60-71.
56. Ayala A, Chaudry IH. Immune dysfunction in murine polymicrobial sepsis: mediators, macrophages, lymphocytes and apoptosis. Shock. 1996;6(suppl 1): S27-S38.
57. Hesse DG, Tracey KJ, Fong Y, et al. Cytokine appearance in Human endotoxemia and primate bacteremia. Surg Gynecol Obstet. 1988;166:147-153.
58. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet. 1987;1:355-357.
59. Girardin E, Grau JM, Dayer JM, Roux-Lombard P, Lambert PH. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med. 1988;319:397-400.
60. Marano MA, Fong Y, Moldawer LL, et al. Serum cachectin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality. Surg Gynecol Obstet 1990;170:32-38.
61. Debets JM, Kampmeijer R, van der Linden MP, Buurman WA, van der Linden CJ. Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med. 1989;17:489-494.
62. Cannon JG, Friedberg JS, Gelfand JA, Tompkins RG, Burke JF, Dinarello CA. Circulating interleukin-1α and tumor necrosis factor-α concentrations after burn injury in humans. Crit Care Med. 1992;20:1414-1419.
63. Calandra T, Baumgartner J, Grau GE, et al, for the Swiss-Dutch JS Immunoglobin Study Group. Prognostic value of turmor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interteron-gamma in the serum of patients with septic shock. J Infect Dis. 1990;161:982-987.
64. Damas P, Reuter A, Gysen P. Demonty J, Lamy M, Franchimont P. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med. 1989;7:975-978.
65. Beutler B, Milsark IW, Cerami A. Passive immunization against cachectin/ tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985;229:869-871.
66. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al, for the HA-1A Sepsis Study Group. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N Engl J Med. 1991;324:429-436.
67. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR, for the CHESS Trial Study Group. Treatment of septic shock with human monoclonal antibody HA-1A: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1994;121:1-5.
68. Kett DH, Quartin AA, Sprung CL, et al. An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody. Crit Care Med. 1994;22:1227-1234.
69. Ayala A, Kisala JM, Felt JA, Perrin MM, Chaudry IH. Does endotoxin tolerance prevent the release of inflammatory monokines (interleukin-1, interleukin-6, or tumor necrosis factor) during sepsis? Arch Surg. 1992;127:191-196.
70. van der Poll T, Coyle SM, Levi M, et al. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood. 1997;89:3727-3734.
71. Cohen J, Calet J. Intersept: an international multicenter, placebo controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis. Crit Care Med. 1996;24:1431-1440.
72. Fisher CJ Jr, Agosti JM, Opal SM, et al, for the Soluble TNF Receptor Sepsis Study Group. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med. 1996;334:1697-1702.
73. Abraham E, Glauser MP, Butler T, et al, for the Ro 45-2081 Study Group. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: a randomized controlled multicenter trial. JAMA. 1997;277:1531-1538.
74. Remick D, Manohar P, Bolgos G, Rodriguez J, Moldawer L, Wollenberg G. Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture. Shock. 1995;4:89-95.
75. Suitters AJ, Foulkes R, Opal SM, et al. Differential effect of isotype on efficacy of anti-tumor necrosis factor-alpha chimeric antibodies in experimental septic shock. J Exp Med. 1994;179:849-856.
76. Silva AT, Appelmelk BJ, Buurman WA, Bayston KF, Cohen J. Monoclonal antibody to endotoxin core protects mice from Escherishia coli sepsis by a mechanism independent of tumor necrosis factor and interleukin-6. J Infect Dis. 1990; 162:454-459.
77. Fiedler VB, Loof I, Sander E, Voehringer V, Galanos C, Fournel MA. Monoclonal antibody to tumor necrosis factor-α prevents lethal endotoxin sepsis in adult rhesus monkeys. J Lab Clin Med. 1992;120:574-588.
78. Abraham E, Wunderink R, Silverman H, et al, for the TNF-α MAb Sepsis Study Group. Efficacy and safety of monoclonal antibody to human tumor necrosis factor a in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. JAMA. 1995;273:934-941.
79. Reinhart K, Wiegand-Lohnert C, Grimminger F, et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med. 1996;24:733-742.
80. O'Reilly M, Silver GM, Davis JH, Gamelli RL, Hebert JC. Interleukin 1 beta improves survival following cecal ligation and puncture. J Surg Res. 1992;52:516-522.
81. Lange JR, Alexander HR, Merino MJ, Doherty GM, Norton JA. Interleukin-1α prevention of the lethality of Escherichia coli peritonitis. J Surg Res. 1992;52: 555-559.
82. Havell EA, Moldawer LL, Helfgott D, Kilian PL, Sehgal HL. Type I IL-1 receptor blockade exacerbates murine listeriosis. J Immunol. 1992;148:1486-1492.
83. Alexander HR, Doherty GM, Buresh CM, Venzon DJ, Norton JA. A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in rats. J Exp Med. 1991;173:1029-1032.
84. Fischer E, Marano MA, Van Zee KJ, et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest. 1992; 89:1551-1557.
85. Fisher CJ Jr, Dhainaut JA, Opal SM, et al, for the Phase III rhIL-1ra Sepsis Syndrome Study Group. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA. 1994;271:1836-1843.
86. Deitch EA. Animal models of sepsis and shock: a review and lessons learned. Shock. 1998;9:1-11.
87. Marshall JC. The failure of clinical trials in sepsis: challenges of clinical trial design. In: Redl H, Schlag G, eds. Cytokines in Severe Sepsis and Septic Shock. 1999:349-362.
88. Dellinger RP. Post hoc analyses in sepsis trials: a formula for disappointment? Crit Care Med. 1996;24:727-729.
89. Petros AJ, Marshall JC, Van Saene HKF. Should morbitity replace mortality as an endpoint for clinical trials in intensive care? Lancet. 1995;345:369-371.
90. Morrison DC, Bucklin SE. Evidence for antibiotic-mediated endotoxin release as a contributing factor to lethality in experimental gram-negative sepsis. Scand J Infect Dis Suppl. 1996;101:3-8.
91. Horn DL, Opal SM, Lomastro E. Antibiotics, cytokines, and endotoxin: a complex and evolving relationship in gram-negative sepsis. Scand J Infect Dis Suppl. 1996;101:9-13.
92. Holzheimer RG. The significance of endotoxin release in experimental and clinical sepsis in surgical patients: evidence for antibiotic-induced endotoxin release? Infection. 1998;26:77-84.
93. Holaday JW, Kenner JR, Smith PF, Bryant HU, Berton EW. Neuroendocrine regulation of immune function. In: Faist E, Meakins J, Schildberg FW, eds, Host Defense Dysfunction in Trauma, Shock and Sepsis. New York, NY: Springer-Verlag NY Inc; 1993:59-65.
94. van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF. Epinephrine inhibits tumor necrosis factor-α and potentiates interleukin 10 production during human endotoxemia. J Clin Invest. 1996;97:713-719.
95. Waymack JP, Rapien J, Garnett D, Twedell JS, Alexander JW. Effect of transfusion on immune function in a traumatized animal model. Arch Surg. 1986; 121:50-55.
96. Gianotti L, Pyles T, Alexander JW, Babcock GF, Carey MA. Impact of blood transfusion and burn injury on microbial translocation and bacterial survival. Transfusion. 1992;32:312-317.
97. Shelby J. Transfusion-induced immunosuppression. J Burn Care Rehabil. 1987; 8:546-548.
98. Donnelly PK, Proud G, Shenton BK, Taylor RM. Transfusion-induced immunosuppression and red cell clearance. Transfus Med. 1991;1:217-221.
99. Salinas JC, Cabezali R, Torcal J, et al. Immune response and cytokines in septic rats undergoing blood transfusion. J Surg Res. 1998;80:295-299.
100. Zellweger R, Ayala A, Stein S, DeMaso CM, Chaudry IH. Females in proestrus state tolerate sepsis better than males. Crit Care Med. 1997;25:106-110.
101. Bone RC. Toward an epidemiology and natural history of SIRS. JAMA. 1992; 268:3452-3455.
102. Schroder J, Kahlke V, Staubach KH, Zabel P, Stuber F. Gender differences in human sepsis. Arch Surg. 1998;133:1200-1205.
103. Kahlke V, Angele MA, Schwacha MG, et al. Gender and age are important factors that influence immune responses after trauma-hemorrhage [abstract]. Shock. 1999;11:70.
104. Zellweger R, Wichmann MW, Ayala A, Chaudry IH. Metoclopramide: a novel and safe immunomodulating agent for restoring the depressed macrophage function following trauma-hemorrhage. J Trauma. 1998;44:70-77.
105. Meldrum DR, Ayala A, Chaudry IH. Mechanism of diltiazem's immunomodulatory effects after hemorrhage and resuscitation. Am J Physiol. 1993;265: C412-C421.
106. Ertel W, Morrison MH, Ayala A, Chaudry IH. Chloroquine attenuates hemorrhagic shock induced suppression of Kupffer cell antigen presentation and MHC class II antigen expression through blockade of tumor necrosis factor and prostaglandin release. Blood. 1991;78:1781-1788.
107. Wichmann MW, Angele MK, Ayala A, Cioffi WG, Chaudry I. Flutamide: a novel agent for restoring the depressed cell-mediated immunity following soft-tissue trauma and hemorrhagic shock. Shock. 1997;8:242-248.
108. Angele MK, Cantania RA, Ayala A, Cioffi WG, Bland KI, Chaudry IH. Dehydroepiandrosterone: an inexpensive steriod hormone that decreases the mortality due to sepsis following trauma-induced hemorrhage. Arch Surg. 1998;133: 1281-1288.